SEC Form 4 · accession 0001209191-16-137392
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore H Stanley
Director
Period of report
Aug 16, 2016
Accepted (ET)
Aug 16, 2016 · 8:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 16, 2016 | M | 15,000 | $5.96 | A | 17,000 | D | |
| Common StockF1 | Aug 16, 2016 | S | 15,000 | $18.02 | D | 2,000 | D | |
| Common StockF1 | holding | — | — | — | 6,000 | I | by non-profit corporation | |
| Common StockF2 | holding | — | — | — | 10,200 | I | by limited partnership |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F3,F4 | $5.96 | Aug 16, 2016 | M | 15,000 | D | — | Aug 12, 2023 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The Reporting Person disclaims beneficial ownership of the Securities except to the extent of his pecuriniary interest therein.
- F3The exercise price reflects a 3-for-2 forward stock split effected by the Issuer on March 28, 2014 and a 2-for-1 forward stock split effected by the Issuer on June 5, 2015.
- F4One third of the shares subject to the option vested on August 12, 2014 and the remainder vested in 24 equal monthly installments thereafter until fully vested and exercisable on August 12, 2016.
- F5On March 27, 2014 and June 5, 2015 the Issuer effected a 3-for-2 forward stock split and a 2-for-1 forward stock split, respectively, both pursuant to a stock dividend, resulting in the reporting person's ownership of an aggregate of 15,000 additional options.